Insight Molecular Diagnostics Inc.
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | – | $-0.31 | $-0.23 |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | – | $-0.12 | $-0.28 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | $1.10M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | – | $-0.34 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | During market hours | – | $-0.30 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | $2.14M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | During market hours | $1.50M | $-1.93 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | – | $-0.98 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 12, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
Press releases
Announcements Insight Molecular Diagnostics filed with the SEC
Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Results of operations · EX-99.1 to Form 8-K
Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
Results of operations · EX-99.1 to Form 8-K
ANNOUNCES $26.0 MILLION REGISTERED DIRECT OFFERING
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch
Results of operations · EX-99.1 to Form 8-K
Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
Results of operations · EX-99.1 to Form 8-K
Changes Name to Insight Molecular
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
letter to our shareholders from iMDx Chief Executive Officer Josh Riggs
Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Reports Q1 2025 Results and Business Progress
Results of operations · EX-99.1 to Form 8-K
Reports Successful 2024; Sets Stage for 2025 Catalysts
Results of operations · EX-99.1 to Form 8-K
Prices $29.1 Million Equity Offering
Material agreement · Agreement terminated · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Signs Leading Transplant Centers in US and Germany
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Announces Successful GraftAssure TM Beta Launch and Q2 2024 Results
Results of operations · EX-99.1 to Form 8-K
REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
REPORTS Full Year 2023 FINANCIAL RESULTS
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
and Bio-Rad Partner on Global Launch of Transplant Assay
Material agreement · Other events · EX-99.1 to Form 8-K
are excited to announce the official launch of #VitaGraft Kidney!
Regulation FD disclosure · EX-99.1 to Form 8-K
REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
Results of operations · Executive or director change · EX-99.1 to Form 8-K
ANNOUNCES 1-for-20 reverse stock split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · Executive or director change · EX-99.1 to Form 8-K
REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS and PLANS TO FILE FORM 12b-25 to extend filing date of its form
Results of operations · EX-99.1 to Form 8-K
Appoints Joshua Riggs as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
February 16, 2023, Oncocyte Corporation (“Oncocyte” or the “Company”) completed its sale of 3,188,181 shares
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
retains 30% stake while eliminating operating expense and future development obligations
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Announces Initiatives to Focus Corporate Strategy
Material agreement · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2022 Financial Results
Results of operations · Exit or restructuring costs · Executive or director change · EX-99.1 CHARTER to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2022 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
Material agreement · Other events · EX-99.1 to Form 8-K
CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS
Material agreement · Other events · EX-99.2 to Form 8-K
Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K